Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: HBV Immunity in SCD HSCT
NCT05200338Unknown
- Sponsor
- University of Amsterdam
- Start
- Jun 2021
- Primary completion
- Jan 2024
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Open-label trial of Hepatitis B vaccine in hepatitis B (HBV) (5 arms), sponsored by University of Amsterdam. Primary endpoint: Proportion of SCD patients with a preserved anti-HBs response. Status: unknown.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05200338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200338.